Actualizado 15/11/2006 09:03
- Comunicado -

Long-Term Data Show Aptivus(R) (tipranavir) Continues to Outperform Group of Protease Inhibitors in RESIST Trials (y 3)

Adverse events should be reported to Boehringer Ingelheim Drug Safety on 0800-328-1627 (freephone). Information about adverse event reporting can be found at http://www.yellowcard.gov.uk

SPC ref: A2/UK/SPC/3

Judith von Gordon, CD Communications, Boehringer Ingelheim GmbH, +49-6132-773582, Fax: +49-6132-776601